Severe acute renal failure after exposure to sirolimus-tacrolimus in two livin donor kidney reciplents
- 1 January 2003
- journal article
- case report
- Published by Wolters Kluwer Health in Transplantation
- Vol. 75 (1) , 157-160
- https://doi.org/10.1097/00007890-200301150-00029
Abstract
We began a clinical trial in African Americans comparing sirolimus-tacrolimus to standard immunosuppression. We report two African American male living donor kidney recipients who developed acute renal failure after exposure to sirolimus-tacrolimus. Both patients received similar doses of sirolimus and tacrolimus to achieve target levels of 5 to 15 ng/mL and prednisone in tapering doses. Renal function and tacrolimus and sirolimus levels were systematically monitored. Although both kidneys functioned immediately, acute oliguric renal failure developed approximately 2 weeks after transplantation. Transplant kidney biopsy showed acute tubular necrosis in patient 2. Sirolimus-tacrolimus was then stopped in both patients. Both patients required temporary hemodialysis. Renal function returned 2 weeks later and was normal 2 months after transplantation on tacrolimus plus mycophenolate mofetil. Combination sirolimus-tacrolimus may cause nephrotoxicity in some patients by mechanisms that are presently unexplained.Keywords
This publication has 11 references indexed in Scilit:
- Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cellsAmerican Journal of Physiology-Renal Physiology, 2001
- Safety and efficacy of TOR inhibitors and other immunosuppressive regimens in African-American renal transplant recipientsAmerican Journal of Kidney Diseases, 2001
- Simultaneous simple and fast quantification of three major immunosuppressants by liquid chromatography—tandem mass-spectrometryClinical Biochemistry, 2001
- Clinical Pharmacokinetics of SirolimusClinical Pharmacokinetics, 2001
- Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre studyThe Lancet, 2000
- EFFECT OF TACROLIMUS (FK506) AND SIROLIMUS (RAPAMYCIN) MONO- AND COMBINATION THERAPY IN PROLONGATION OF RENAL ALLOGRAFT SURVIVAL IN THE MONKEY1Transplantation, 2000
- Sirolimus-tacrolimus combination immunosuppressionThe Lancet, 2000
- Renal Endothelin in FK506-Induced Nephrotoxicity in Spontaneously Hypertensive RatsThe Japanese Journal of Pharmacology, 1998
- Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506Kidney International, 1996
- NEPHROTOXICITY FOLLOWING ORTHOTOPIC LIVER TRANSPLANTATIONTransplantation, 1994